Join
Live feed
·
NEWSReleasevia Quantisnow
Aptevo Therapeutics Inc. logo

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

ByQuantisnow·Wall Street's wire, on your screen.
APVO· Aptevo Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APVO (Aptevo Therapeutics Inc.) and more on Quantisnow.